中华实验外科杂志
中華實驗外科雜誌
중화실험외과잡지
CHINESE JOURNAL OF EXPERIMENTAL SURGERY
2012年
6期
1047-1049
,共3页
朱建国%江福能%毕学成%韩兆冬%何慧婵%钟惟德
硃建國%江福能%畢學成%韓兆鼕%何慧嬋%鐘惟德
주건국%강복능%필학성%한조동%하혜선%종유덕
细胞因子通路抑制因子3%实时荧光定量聚合酶链反应%免疫组织化学%前列腺癌
細胞因子通路抑製因子3%實時熒光定量聚閤酶鏈反應%免疫組織化學%前列腺癌
세포인자통로억제인자3%실시형광정량취합매련반응%면역조직화학%전렬선암
Suppressors of cytokine signaling-3%Real-time fluorescent quantitative polymerase chain reaction%Immunohistochemistry%Prostate cancer
目的 检测细胞因子通路抑制因子3( SOCS3)在前列腺癌和前列腺增生组织中的表达,分析其表达水平与临床病理参数的关系,探讨SOCS3在前列腺癌中的意义.方法 通过实时荧光定量聚合酶链反应(RT-qPCR)检测SOCS3基因在前列腺癌、前列腺增生组织中的表达,免疫组织化学技术检测前列腺癌、前列腺增生组织中SOCS3蛋白的表达,结合SOCS3免疫组织化学评分与前列腺癌患者临床病理参数进行分析.结果 相对于前列腺增生组织,前列腺癌患者组织中SOCS3表达下调(P<0.01);49例前列腺癌组织有26例阳性,29例前列腺增生组织有22例染色阳性,SOCS3在前列腺增生组织的染色强于前列腺癌组织(P<0.05);SOCS3表达与前列腺癌患者血清前列腺特异性抗原(PSA)水平(P<0.01)、Gleason评分(P<0.05)和肿瘤TNM分期呈负相关(P<0.01),与肿瘤转移呈正相关(P<0.01),与年龄无明显相关(P>0.05).结论 检测SOCS3可鉴别前列腺癌和前列腺增生;在前列腺癌中SOCS3表达下调可抑制前列腺癌的进展,表达上调促进前列 腺癌转移.
目的 檢測細胞因子通路抑製因子3( SOCS3)在前列腺癌和前列腺增生組織中的錶達,分析其錶達水平與臨床病理參數的關繫,探討SOCS3在前列腺癌中的意義.方法 通過實時熒光定量聚閤酶鏈反應(RT-qPCR)檢測SOCS3基因在前列腺癌、前列腺增生組織中的錶達,免疫組織化學技術檢測前列腺癌、前列腺增生組織中SOCS3蛋白的錶達,結閤SOCS3免疫組織化學評分與前列腺癌患者臨床病理參數進行分析.結果 相對于前列腺增生組織,前列腺癌患者組織中SOCS3錶達下調(P<0.01);49例前列腺癌組織有26例暘性,29例前列腺增生組織有22例染色暘性,SOCS3在前列腺增生組織的染色彊于前列腺癌組織(P<0.05);SOCS3錶達與前列腺癌患者血清前列腺特異性抗原(PSA)水平(P<0.01)、Gleason評分(P<0.05)和腫瘤TNM分期呈負相關(P<0.01),與腫瘤轉移呈正相關(P<0.01),與年齡無明顯相關(P>0.05).結論 檢測SOCS3可鑒彆前列腺癌和前列腺增生;在前列腺癌中SOCS3錶達下調可抑製前列腺癌的進展,錶達上調促進前列 腺癌轉移.
목적 검측세포인자통로억제인자3( SOCS3)재전렬선암화전렬선증생조직중적표체,분석기표체수평여림상병리삼수적관계,탐토SOCS3재전렬선암중적의의.방법 통과실시형광정량취합매련반응(RT-qPCR)검측SOCS3기인재전렬선암、전렬선증생조직중적표체,면역조직화학기술검측전렬선암、전렬선증생조직중SOCS3단백적표체,결합SOCS3면역조직화학평분여전렬선암환자림상병리삼수진행분석.결과 상대우전렬선증생조직,전렬선암환자조직중SOCS3표체하조(P<0.01);49례전렬선암조직유26례양성,29례전렬선증생조직유22례염색양성,SOCS3재전렬선증생조직적염색강우전렬선암조직(P<0.05);SOCS3표체여전렬선암환자혈청전렬선특이성항원(PSA)수평(P<0.01)、Gleason평분(P<0.05)화종류TNM분기정부상관(P<0.01),여종류전이정정상관(P<0.01),여년령무명현상관(P>0.05).결론 검측SOCS3가감별전렬선암화전렬선증생;재전렬선암중SOCS3표체하조가억제전렬선암적진전,표체상조촉진전렬 선암전이.
Objective To study the expression of suppressors of cytokine signaling-3 (SOCS3) in prostate cancer (PCa) and benign prostate hyperplasia ( BPH ) tissues,analysis of its expression level with clinical pathological parameters and to explore the significance of SOCS3 in PCa.Methods Using real time fluorescent quantitative polymerase chain reaction (RT-qPCR) to detect the expression of SOCS3 in PCa and BPH tiussues,immunohistochemical (IHC) validation,the combination of SOCS3 staining score and clinical pathological parameters were analyzed.Results The expression of SOCS3 in BPH tissues was significantly higher than that in PCa tissues ( P < 0.01 ),22 of 29 cases of BPH were SOCS3 staining positive,PCa tissues only 26 cases showed positive,the expression of SOCS3 in BPH tissue was significantly stronger than that of PCa tissues ( P < 0.05 ) ; Combined with SOCS3 stain score and the clinicopathological parameters of the corresponding PCa patients,we found that the low expression of SOCS3 was closely related with serum prostate specific antigen (PSA) level ( P < 0.01 ),Gleason score ( P < 0.05 ),tumor TNM stage (P<0.01) and metastasis (P<0.01) but not with age (P>0.05).Conclusion Detection of SOCS3 can identify PCa and BPH; downregulation of SOCS3 may irhibit the progression of PCa,whereas upregulation promote metastasis.